Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company
Tweet Send to a Friend
Leerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
